Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQT Study of Orelabrutinib in Healthy Subjects
NCT05660720Phase 1Unknown
- Sponsor
- InnoCare Pharma
- Start
- Nov 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of orelabrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (4 arms), sponsored by InnoCare Pharma. Primary endpoint: Placebo-corrected change-from-baseline QTcF interval at Day 17. Status: unknown.
02
Drugs
orelabrutinib
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05660720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660720.